Which drug class does brigatinib belong to?

Brigatinib belongs to a specific class of antineoplastic drugs, more specifically, it is an alkaloid antineoplastic drug and an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. This drug plays an important role in the treatment of non-small cell lung cancer (NSCLC), especially for patients with ALK gene rearrangements or mutations.

Brigatinib, as an alkaloid drug, has anti-tumor activity. Alkaloids are a class of nitrogen-containing organic compounds that are commonly found in plants and have a variety of biological activities, including anti-tumor effects.

Brigatinib is a reversible inhibitor ofALK. ALK is a protein kinase that is abnormally expressed in a variety of cancers, particularly in certain types of non-small cell lung cancer. By inhibiting the activity of ALK, brigatinib blocks the growth and spread of cancer cells.

Tyrosine kinases are a class of enzymes that play a key role in cell signaling. By inhibiting the activity of these enzymes, brigatinib interferes with the signaling pathways of cancer cells, thereby inhibiting tumor growth.

Brigatinib is highly selective for patients with NSCLC whose ALK gene rearrangement means it can target cancer cells more precisely and reduce damage to normal cells. Clinical studies have shown that brigatinib can significantly shrink tumors and extend patients' progression-free survival. Brigatinib has the ability to penetrate the blood-brain barrier, which is particularly important for the treatment of NSCLC patients with brain metastases. Compared with other chemotherapy drugs, brigatinib has relatively few side effects, and patients usually tolerate the treatment well.

References:

https://medlineplus.gov/druginfo/meds/a617016.html